Journal article
Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
Abstract
Background/Aims: In patients receiving ustekinumab (UST) for treatment of Crohn's disease, there is no proven strategy to enhance or re-capture response. We assessed the utility of UST intravenous (IV) reinduction (~6 mg/kg) to achieve clinical, biochemical and endoscopic response or remission, in patients with partial or loss of response to UST maintenance therapy.
Methods: A multicentre, retrospective cohort study was performed. Adults who …
Authors
Heron V; Fraine SL; Panaccione N; Restellini S; Germain P; Candido K; Bernstein CN; Bessissow T; Bitton A; Chauhan UK
Journal
Journal of the Canadian Association of Gastroenterology, Vol. 5, No. 5, pp. 208–213
Publisher
Oxford University Press (OUP)
Publication Date
October 3, 2022
DOI
10.1093/jcag/gwac017
ISSN
2515-2084